Cargando…
Redefining the polypill: pros and cons in cardiovascular precision medicine
Polypill is a multi-drug formulation in a single pill intended to simplify the drug regimen and reduce medication-induced adverse effects. The most common multidrug combinations in a polypill are used to treat cardiovascular diseases and are targeted against key modifiable risk factors such as hyper...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549989/ https://www.ncbi.nlm.nih.gov/pubmed/37799963 http://dx.doi.org/10.3389/fphar.2023.1268119 |
_version_ | 1785115437631012864 |
---|---|
author | Birla, Siddharth Angural, Arshia Madathumchalil, Arya Shende, Ritika V. Shastry, Sharvani V. Mahadevappa, Manjappa Shambhu, Sunil Kumar Vishwanath, Prashant Prashant, Akila |
author_facet | Birla, Siddharth Angural, Arshia Madathumchalil, Arya Shende, Ritika V. Shastry, Sharvani V. Mahadevappa, Manjappa Shambhu, Sunil Kumar Vishwanath, Prashant Prashant, Akila |
author_sort | Birla, Siddharth |
collection | PubMed |
description | Polypill is a multi-drug formulation in a single pill intended to simplify the drug regimen and reduce medication-induced adverse effects. The most common multidrug combinations in a polypill are used to treat cardiovascular diseases and are targeted against key modifiable risk factors such as hypertension and hyperlipidemia. These contain blood-pressure lowering agents, statins, and anti-platelet agents usually in a fixed dose. Polypills can be an affordable therapeutic intervention for treating high-risk patients, as these are proven to increase patients’ adherence to medication and improve clinical outcomes. Over the previous years, randomized clinical trials of several polypills have yielded contradictory findings, raising skepticism regarding their widespread use in primary disease prevention. Here, we have reviewed the concept of polypills, the evidence-based strengths, the limitations of this polypharmacy intervention strategy, and discussed future directions for their use in the primary and secondary preventive management of cardiovascular diseases and associated risk factors. |
format | Online Article Text |
id | pubmed-10549989 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105499892023-10-05 Redefining the polypill: pros and cons in cardiovascular precision medicine Birla, Siddharth Angural, Arshia Madathumchalil, Arya Shende, Ritika V. Shastry, Sharvani V. Mahadevappa, Manjappa Shambhu, Sunil Kumar Vishwanath, Prashant Prashant, Akila Front Pharmacol Pharmacology Polypill is a multi-drug formulation in a single pill intended to simplify the drug regimen and reduce medication-induced adverse effects. The most common multidrug combinations in a polypill are used to treat cardiovascular diseases and are targeted against key modifiable risk factors such as hypertension and hyperlipidemia. These contain blood-pressure lowering agents, statins, and anti-platelet agents usually in a fixed dose. Polypills can be an affordable therapeutic intervention for treating high-risk patients, as these are proven to increase patients’ adherence to medication and improve clinical outcomes. Over the previous years, randomized clinical trials of several polypills have yielded contradictory findings, raising skepticism regarding their widespread use in primary disease prevention. Here, we have reviewed the concept of polypills, the evidence-based strengths, the limitations of this polypharmacy intervention strategy, and discussed future directions for their use in the primary and secondary preventive management of cardiovascular diseases and associated risk factors. Frontiers Media S.A. 2023-09-19 /pmc/articles/PMC10549989/ /pubmed/37799963 http://dx.doi.org/10.3389/fphar.2023.1268119 Text en Copyright © 2023 Birla, Angural, Madathumchalil, Shende, Shastry, Mahadevappa, Shambhu, Vishwanath and Prashant. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Birla, Siddharth Angural, Arshia Madathumchalil, Arya Shende, Ritika V. Shastry, Sharvani V. Mahadevappa, Manjappa Shambhu, Sunil Kumar Vishwanath, Prashant Prashant, Akila Redefining the polypill: pros and cons in cardiovascular precision medicine |
title | Redefining the polypill: pros and cons in cardiovascular precision medicine |
title_full | Redefining the polypill: pros and cons in cardiovascular precision medicine |
title_fullStr | Redefining the polypill: pros and cons in cardiovascular precision medicine |
title_full_unstemmed | Redefining the polypill: pros and cons in cardiovascular precision medicine |
title_short | Redefining the polypill: pros and cons in cardiovascular precision medicine |
title_sort | redefining the polypill: pros and cons in cardiovascular precision medicine |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549989/ https://www.ncbi.nlm.nih.gov/pubmed/37799963 http://dx.doi.org/10.3389/fphar.2023.1268119 |
work_keys_str_mv | AT birlasiddharth redefiningthepolypillprosandconsincardiovascularprecisionmedicine AT anguralarshia redefiningthepolypillprosandconsincardiovascularprecisionmedicine AT madathumchalilarya redefiningthepolypillprosandconsincardiovascularprecisionmedicine AT shenderitikav redefiningthepolypillprosandconsincardiovascularprecisionmedicine AT shastrysharvaniv redefiningthepolypillprosandconsincardiovascularprecisionmedicine AT mahadevappamanjappa redefiningthepolypillprosandconsincardiovascularprecisionmedicine AT shambhusunilkumar redefiningthepolypillprosandconsincardiovascularprecisionmedicine AT vishwanathprashant redefiningthepolypillprosandconsincardiovascularprecisionmedicine AT prashantakila redefiningthepolypillprosandconsincardiovascularprecisionmedicine |